Core Viewpoint - HCM's stock price increased by 3.39% on August 13, reaching $15.86 per share, with a total market capitalization of $2.766 billion [1] Financial Performance - As of June 30, 2025, HCM reported total revenue of $278 million, a year-on-year decrease of 9.16% [1] - The company achieved a net profit attributable to shareholders of $455 million, reflecting a significant year-on-year increase of 1663.32% [1] Company Overview - HCM is recognized as one of China's first innovative pharmaceutical research and development companies focused on the global market [1] - Over the past 20 years, the company has established a comprehensive and integrated R&D innovation platform with world-class discovery and development capabilities [1] - HCM is dedicated to bringing its self-discovered anti-tumor drug candidates to global patients, with three drugs already launched in China and the first drug also available in the United States [1] - The company has built a profitable commercial platform in China for the production, marketing, and distribution of its innovative oncology drugs, prescription drugs, and consumer healthcare products [1] - HCM is listed on the NASDAQ Global Select Market, Hong Kong Stock Exchange, and AIM market of the London Stock Exchange (NASDAQ/LSE: HCM; Hong Kong Stock Exchange: 13) [1]
和黄医药(US ADR)上涨3.39%，报15.86美元/股，总市值27.66亿美元